Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: Vasomotor symptoms, bleeding patterns, and serum lipids

International Journal of Fertility and Women's Medicine

Volumn 42, Issue SUPPL. 2, 1997, Pages 376-387

  Rozenberg, Serge ^a   Ylikorkala, Olavi ^b   Arrenbrecht, Stefan ^c  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF HELSINKI   (Finland)

^c RW Johnson Pharmaceutical Res I   (Switzerland)

Author keywords

Estradiol; Hormone replacement therapy; Hot flushes; Menopause; Norethisterone; Progestogen; Transdermal; Vaginal bleeding

Indexed keywords

ESTROGEN; GESTAGEN; LIPOPROTEIN A; NORETHISTERONE;

ADULT; AGED; ARTICLE; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE TOLERANCE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LIVER METABOLISM; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; TRANSDERMAL DRUG ADMINISTRATION; TRIACYLGLYCEROL BLOOD LEVEL; VAGINA BLEEDING;

EID: 0031406688     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. European Menopause Society: European consensus development conference on menopause. Hum Reprod 11:975-979, 1996.
2. Stevenson JC, Drook D, Godsland IF: Oral versus transdermal hormone replacement therapy. Int J Fertil 38(Suppl 1):30-35, 1993.
3. Baker VL: Alternatives to oral estrogen replacement: transdermal patches, percutaneous gels, vaginal creams and rings, implants, and other methods of delivery. Obstet Gynecol Clin N Am 21:271-297, 1994.
4. Udoff L, Langenberg P, Adashi EY: Combined continuous hormone replacement therapy: a critical view. Obstet Gynecol 86:306-316, 1995.
5. Van Leusden HAIM, Albertyn G, Verlaine C, et al: A comparative multicenter study of two transdermal estradiol replacement therapies in the treatment of postmenopausal symptoms. Int J Fertil 38:210-218, 1993.
6. Siedel J, Hägele EO, Ziegenhorn J, et al: Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 29:1075-1080, 1983.
7. Kattermann R, Jaworek D, Möller G, et al: Multicentre study of a new enzymatic method of cholesterol determination. J Clin Chem Clin Biochem 22:245- 251, 1984.
8. Trinder P: Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 6:24-27, 1969.
9. Ballantyne FC, Clark RS, Simpson HS, et al: High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects. Metabolism 31:433-437, 1982.
10. Gidez LI, Miller GJ, Burstein M, et al: Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res 23:1206-1223, 1982.
11. Sandkamp M, Funke H, Schulte H, et al: Lipoprotein (a) is an independent risk factor for myocardial infarction at a young age. J Clin Chem 36:20-23, 1990.
12. Kostner GM, Gries A, Pometta M, et al: Immunological determination of lipoprotein Lp (a): comparison of Laurell electrophoresis and ELISA. Clin Chem Acta 188:187-192, 1990.
13. Whitehead MI, Hillard TC, Crook D: The role and use of progestogens. Obstet Gynecol 75(Suppl):S59- S76, 1990.
14. Archer DF, Pickar JH, Bottiglioni F, for the Menopause Study Group: Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 83:686-692, 1994.
15. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273:199-208, 1995.
16. Bush TL, Barrett-Connor E, Cowan LD, et al: Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 75:1102-1109, 1987.
17. Sullivan JM, Fowlkes LP: Estrogens, menopause, and coronary artery disease. Cardiol Clin 14:105-116, 1996.
18. Castelli WP, Anderson K: A population at risk: prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med 80(Suppl 2A):23-32, 1986.
19. Walsh BW, Schiff I, Rosner B, et al: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325:1196-1204, 1991.
20. Mattsson L-A, Samsioe G, von Schoultz B, et al: Transdermally administered oestradiol combined with oral medroxyprogesterone acetate: the effects on lipoprotein metabolism in postmenopausal women. Br J Obstet Gynaecol 100:450-453, 1993.
21. Lobo RA, Pickar JH, Wild RA, et al, for the Menopause Study Group: Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 84:987-995, 1994.
22. Lobo RA, Notelovitz M, Bernstein L, et al: Lp (a) lipoprotein: relationship to cardiovascular disease risk factors, exercise, and estrogen. Am J Obstet Gynecol 166:1182-1190, 1992.
23. Wiseman LR, McTavish D: Transdermal estradiol/ norethisterone: a review of its pharmacological properties and clinical use in postmenopausal women. Drugs Aging 4:238-256, 1994.
24. Cheang A, Sitruk-Ware R, Utian WH: A risk-benefit appraisal of transdermal estradiol therapy. Drug Safety 9:365-379, 1993.